Variables | Immunological failure | Crude HR (95% CI) | P | Adjusted HR (95% CI) | P | |
---|---|---|---|---|---|---|
 | No | Yes |  |  |  |  |
 | no (%) | no (%) |  |  |  |  |
Gender | Â | Â | Â | Â | Â | Â |
  Female | 102(71.8) | 40(28.2) | 1 |  | 1 |  |
  Male | 209(81) | 49(19) | 1.54(1.02-2.34) | 0.042 | 1.6(1.01-2.68) | 0.046 |
Age (in year) | Â | Â | Â | Â | Â | Â |
  16-30 | 130(78.8) | 35(21.2) | 1 |  |  |  |
  31-50 | 164(77.7) | 47(22.3) | 1.06(.68-1.63) | 0.812 |  |  |
  > 50 | 17(70.8) | 7(29.2) | 1.37(.61-3.09) | 0.443 |  |  |
Education | Â | Â | Â | Â | Â | Â |
  Primary and below | 175(76.8) | 53(23.2) | 1.12(.75-1.74) | 0.546 |  |  |
  Secondary and above | 136(79.1) | 36(20.9) | 1 |  |  |  |
WHO HIV clinical stage | Â | Â | Â | Â | Â | Â |
  I | 47(82.5) | 10(17.5) | 1 |  |  |  |
  II | 65(75.6) | 21(24.4) | 1.44(.69-3.06) | 0.344 |  |  |
  III | 161(77.4) | 47(22.6) | 1.31(.66-2.59) | 0.438 |  |  |
  IV | 38(77.6) | 11(22.4) | 1.32(.56-3.12) | 0.525 |  |  |
Baseline CD4+ count (cells/mm 3 ) | Â | Â | Â | Â | Â | Â |
  0-99 | 87(69.6) | 38(30.4) | 1.72(1.13-2.62) | 0.012 | 1.8(1.10-2.92) | 0.023 |
  ≥100 | 224(81.5) | 51(18.5) | 1 |  | 1 |  |
Initial ART regimen | Â | Â | Â | Â | Â | Â |
  D4T/3TC/NVP or EFV | 40(81.6) | 9(18.4) | 1 |  |  |  |
  AZT/3TC/NVP or EFV | 141(74.6) | 48(25.4) | 0.90(.43-1.89) | 0.785 |  |  |
  TDF/3TC/NVP or EFV | 130(80.2) | 32(19.8) | 1.29(.83-2.02) | 0.262 |  |  |
Functional status | Â | Â | Â | Â | Â | Â |
  Working | 262(77.1) | 78(22.9) | 1 |  |  |  |
  Ambulatory | 39(79.6) | 10(20.4) | 1.44(.72-2.92) | 0.301 |  |  |
  Bed ridden | 10(90.9) | 1(9.1) | 1.26(.58-2.75) | 0.555 |  |  |
Incident TB | Â | Â | Â | Â | Â | Â |
  Yes | 16(61.5) | 10(38.5) | 1.92(.99-3.72) | 0.050 | 2.2(0.94-5.09) | 0.063 |
  No | 295(78.9) | 79(21.1) | 1 |  | 1 |  |